Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE Sites - First in Africa

 Pfizer Identifies Synexus' South African Clinical Research Sites as INSPIRE
                           Sites - First in Africa

PR Newswire

MANCHESTER, England, June 12, 2013

MANCHESTER, England, June 12, 2013 /PRNewswire/ --

Three of Synexus' South African dedicated clinical research centres Stanza,
Watermeyer and Nyeleti have been identified by Pfizer as meeting the exacting
standards that the company demands to join a worldwide network of INSPIRE
sites which must be both highly productive and effective.

INSPIRE, which stands for Investigator Networks, Site Partnerships and
Infrastructure for Research Excellence, means that these sites have early
access to Pfizer's portfolio data and advanced information regarding the
clinical trials to be sponsored by Pfizer. They are also involved in
publications in scientific journals, protocol design, advisory boards and the
sharing of best practice across the INSPIRE network.

Synexus, which is the world's largest multi-national company focused on the
recruitment and running of clinical trials, already has an INSPIRE site in
Wroclaw Poland.

Tebogo Sebata, Investigator Site Development and Support Lead, Pfizer Global
commented, "We are really delighted that we have been able to identify these
sites and add them to our INSPIRE network. We put in place the INSPIRE
programme so that we can work with the best sites across the world. Centres
which have real expertise in the science of clinical trials, the
infrastructure support that is necessary, proven recruitment strategies and
the in depth knowledge can help us maximize our development programmes going

Dr Sanet Aspinall, Managing Director of Synexus South Africa, commented, "We
are thrilled to have been invited to become part of the INSPIRE network. We
have had to go through an exhaustive assessment programme which looked at our
previous experience, expertise across a range of therapeutic areas,
infrastructure and resources and effective recruitment strategies. This is not
only excellent for our company but for South Africa as it shows that it is a
very good place in which to carry out clinical trials."

Dr Glynis Neagle, Chief Medical Officer for Synexus concluded, "We are really
focussed on providing our clients with quality patients and data. To do this,
we are training our doctors and clinical staff in the medical science of the
therapy areas we focus on; cardiovascular, metabolic (diabetes and obesity),
bone, respiratory, infectious diseases and CNS (dementia and pain). Our
investigators are experts in clinical trials and apply this knowledge to each
trial which gives added value to clients."

Simon Vane Percy
+ 44-(0)1737-821-890

SOURCE Synexus
Press spacebar to pause and continue. Press esc to stop.